1,1 ′-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins
US10730902B2 · kind B2 · utility
0Cited by
1References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2016 |
| Grant date | Aug 4, 2020 |
| Priority date | — |
| Expiry date | Nov 8, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.